J M Bowen1, I White2, L Smith3, A Tsykin4, K Kristaly2, S K Thompson3, C S Karapetis5, H Tan6, P A Game3, T Irvine7, D J Hussey7, D I Watson7, D M K Keefe2. 1. School of Medical Sciences, University of Adelaide, Adelaide, Australia. joanne.bowen@adelaide.edu.au. 2. School of Medicine, University of Adelaide, Adelaide, Australia. 3. Discipline of Surgery, University of Adelaide, Adelaide, Australia. 4. Centre for Cancer Biology, SA Pathology, Adelaide, South Australia, Australia. 5. School of Medicine, Flinders University, Bedford Park, Australia. 6. RAH Cancer Centre, Royal Adelaide Hospital, Adelaide, Australia. 7. Department of Surgery, Flinders University, Adelaide, South Australia, Australia.
Abstract
PURPOSE: Esophageal cancer has a high mortality rate, and its multimodality treatment is often associated with significant rates of severe toxicity. Effort is needed to uncover ways to maximize effectiveness of therapy through identification of predictive markers of response and toxicity. As such, the aim of this study was to identify genes predictive of chemoradiotherapy-induced gastrointestinal toxicity using an immune pathway-targeted approach. METHODS: Adults with esophageal cancer treated with chemotherapy consisting of 5-fluorouracil and cisplatin and 45-50 Gy radiation were recruited to the study. Pre-therapy-collected whole blood was analyzed for relative expression of immune genes using real-time polymerase chain reaction (RT-PCR). Gene expression was compared between patients who experienced severe regimen-related gastrointestinal toxicity vs. those experiencing mild to moderate toxicity. RESULTS: Blood from 31 patients were analyzed by RT-PCR. Out of 84 immune genes investigated, TNF was significantly elevated (2.05-fold, p = 0.025) in the toxic group (n = 12) compared to the non-toxic group (n = 19). Nausea and vomiting was the most commonly documented severe toxicity. No associations between toxicity and response, age, sex, histology, or treatment were evident. CONCLUSIONS: This study supports evidence of TNF as a predictive biomarker in regimen-related gastrointestinal toxicity. Confirming these findings in a larger cohort is warranted.
PURPOSE:Esophageal cancer has a high mortality rate, and its multimodality treatment is often associated with significant rates of severe toxicity. Effort is needed to uncover ways to maximize effectiveness of therapy through identification of predictive markers of response and toxicity. As such, the aim of this study was to identify genes predictive of chemoradiotherapy-induced gastrointestinal toxicity using an immune pathway-targeted approach. METHODS: Adults with esophageal cancer treated with chemotherapy consisting of 5-fluorouracil and cisplatin and 45-50 Gy radiation were recruited to the study. Pre-therapy-collected whole blood was analyzed for relative expression of immune genes using real-time polymerase chain reaction (RT-PCR). Gene expression was compared between patients who experienced severe regimen-related gastrointestinal toxicity vs. those experiencing mild to moderate toxicity. RESULTS: Blood from 31 patients were analyzed by RT-PCR. Out of 84 immune genes investigated, TNF was significantly elevated (2.05-fold, p = 0.025) in the toxic group (n = 12) compared to the non-toxic group (n = 19). Nausea and vomiting was the most commonly documented severe toxicity. No associations between toxicity and response, age, sex, histology, or treatment were evident. CONCLUSIONS: This study supports evidence of TNF as a predictive biomarker in regimen-related gastrointestinal toxicity. Confirming these findings in a larger cohort is warranted.
Authors: B L D M Brücher; H J Stein; F Zimmermann; M Werner; M Sarbia; R Busch; H J Dittler; M Molls; U Fink; J R Siewert Journal: Eur J Surg Oncol Date: 2004-11 Impact factor: 4.424
Authors: F Fiorica; D Di Bona; F Schepis; A Licata; L Shahied; A Venturi; A M Falchi; A Craxì; C Cammà Journal: Gut Date: 2004-07 Impact factor: 23.059
Authors: Dorothy M Keefe; Linda S Elting; Hoang T Nguyen; Steven M Grunberg; Giuseppe Aprile; Antony Bonaventura; Sudarsha Selva-Nayagam; Andrea Barsevick; Bogda Koczwara; Stephen T Sonis Journal: Cancer Chemother Pharmacol Date: 2014-07-25 Impact factor: 3.333
Authors: Maria A A Cortez; Carlos A Scrideli; José A Yunes; Elvis T Valera; Sílvia R C Toledo; Patrícia C B Pavoni-Ferreira; Maria L M Lee; Antônio S Petrilli; Silvia R Brandalise; Luiz G Tone Journal: Pediatr Blood Cancer Date: 2009-12 Impact factor: 3.167
Authors: Stephen G Maher; Charles M Gillham; Shane P Duggan; Paul C Smyth; Nicola Miller; Cian Muldoon; Kenneth J O'Byrne; Orla M Sheils; Donal Hollywood; John V Reynolds Journal: Ann Surg Date: 2009-11 Impact factor: 12.969
Authors: Richard M Logan; Andrea M Stringer; Joanne M Bowen; Ann S-J Yeoh; Rachel J Gibson; Stephen T Sonis; Dorothy M K Keefe Journal: Cancer Treat Rev Date: 2007-05-15 Impact factor: 12.111
Authors: Komal Singh; Kord M Kober; Steven M Paul; Marilyn Hammer; Fay Wright; Yvette P Conley; Jon D Levine; Christine Miaskowski Journal: Support Care Cancer Date: 2019-08-19 Impact factor: 3.603
Authors: Komal Singh; Huangshen Cao; Christine Miaskowski; Yvette P Conley; Marilyn Hammer; Fay Wright; Jon D Levine; Kord M Kober Journal: Biol Res Nurs Date: 2020-08-20 Impact factor: 2.522
Authors: Komal P Singh; Kord M Kober; Brenda Ernst; Jasgit Sachdev; Melanie Brewer; Qiyun Zhu; Haiwei Gu; Michele Melisko; Steven M Paul; Bruce A Cooper; Marilyn Hammer; Yvette P Conley; Jon D Levine; Christine Miaskowski Journal: Cancer Nurs Date: 2022 May-Jun 01 Impact factor: 2.760